October 2006--A new report finds Boston Scientific Corp. and Johnson & Johnson are losing sales due to doctors’ concerns over the risks posed by drug-coated heart stents. The report from Bloomberg News cites research from consulting group Goodroe Healthcare Solutions that found drug-coated stents accounted for about 88 percent of U.S. stent sales through the second quarter of 2006 and then started declining after the studies became public. The drug-coated stents may be causing an additional 2,160 deaths worldwide each year, according to an editorial published Oct. 11 by the Journal of the American College of Cardiology. Drug coated stents are a $6 billion dollar a year boom to these device companies. (Biz Journals)